全省领先！烟台近年来累计上市投产6款1类新药

Core Insights - Yantai's biopharmaceutical industry has been identified as a key sector under the "14th Five-Year Plan," focusing on extending the industrial chain, enhancing the value chain, and integrating the supply chain [1] Group 1: Industry Overview - As of now, Yantai has 212 biopharmaceutical enterprises, including 6 listed companies, 1 unicorn, and 23 gazelle companies, along with 9 national-level specialized and innovative small giant enterprises [1] - The city has introduced strategic development plans for medical isotopes and marine drugs, positioning its biopharmaceutical cluster among the first national strategic emerging industry clusters [1] Group 2: Infrastructure Development - The "Blue Pharmaceutical Valley" park has been established with a total investment of 12 billion yuan and a construction area of 1.3 million square meters, attracting 34 biopharmaceutical companies [2] - Several specialized parks are under construction, including the IVD medical device industrial park and the international biopharmaceutical valley, contributing to the growth of major enterprises [2] Group 3: Innovation and Ecosystem - Yantai is building a comprehensive vertical ecosystem for the biopharmaceutical industry, covering product R&D, results transformation, inspection and approval, and production and sales [3] - The city has established a high-level innovation system with 1 major research institute and over 100 provincial-level innovation platforms, aiming to facilitate the development of new drugs [3] Group 4: Competitive Advantage - The focus is on two cutting-edge sectors: medical isotopes and radioactive drugs, as well as cell and gene therapy, while also nurturing high-end generics and medical devices [4] - The Blue Pharmaceutical Valley is the largest domestic park with nuclear drug production qualifications, housing significant players in the nuclear medicine field [5]